Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
J Hosp Infect ; 126: 81-86, 2022 Aug.
Article in English | MEDLINE | ID: mdl-35623470

ABSTRACT

BACKGROUND: With the increase in international travel and development of insecticide resistance, a re-emergence of the bed bug has been observed since the 2000s and it is becoming a worldwide public health problem. Hospitals and other medical settings have not been spared, while the cases reported remain limited. However, there are no specific recommendations for the healthcare settings in the literature. AIM: To report our experience of a bed bug infestation in a medical unit, in the French University Hospital Centre of Brest, caused by the admission of a patient carrier in October 2020. We described the practical methods used to control bed bugs infestation, evaluated the cost of this episode and created a specific procedure to take care of at-risk patients or known carriers of bed bugs. FINDINGS: The decision to close the unit for global treatment was taken after the investigations using a sniffer dog revealed that four rooms were infested. The closure lasted 24 days. We estimated the total cost of the infestation to be approximately US$400,000. No other wave of infestation occurred. We created a specific protocol of care for patients who were known carriers or at risk of carriage of bed bugs to graduate a strategy of control. CONCLUSION: Bed bug infestations in health facilities have a major impact on the care of patients and relevant economic consequences. Prevention and education policies are an essential starting point to respond to the scale of the phenomenon.


Subject(s)
Bedbugs , Ectoparasitic Infestations , Animals , Dogs , Ectoparasitic Infestations/epidemiology , Ectoparasitic Infestations/prevention & control , Hospitals, University , Humans
2.
Ann Endocrinol (Paris) ; 83(1): 46-53, 2022 Feb.
Article in English | MEDLINE | ID: mdl-34921812

ABSTRACT

Throughout the world, millions of people suffer from fragilizing osteopathies such as osteomalacia and osteoporosis. Osteomalacia is a rare disorder, corresponding to mineralization abnormalities in adult bone, as opposed to rickets in children. Renal phosphate loss and hypophosphatasia are the main causes of vitamin-resistant osteomalacia. Diagnosis is based on clinical history, phosphocalcic metabolism assessment and, if necessary, molecular characterization, and must be rapid in order to initiate the most appropriate treatment and consider new treatments such as burosumab if necessary. Osteoporosis is characterized by reduced bone mass and strength, which increases the risk of fragility fracture. Fracture-related burden is expected to increase over the coming decades linked to the aging of population and a treatment gap. In order to reduce this treatment gap, it is important to develop two strategies: improvement of screening and of treatment. Systematic screening using the FRAX® fracture risk assessment tool could be useful to increase anti-osteoporosis medical treatment and reduce fracture rates. The question of treatment sequencing in osteoporosis is another challenge, notably after denosumab cessation, complicated by a decrease in bone mineral density and increased risk of fracture. New treatments are also available, including romosozumab, a humanized monoclonal antibody, which promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab is approved in several countries, including France, for treating severe osteoporosis in postmenopausal women at high risk of fracture and free of cardiovascular comorbidity. Endocrinologists need to be aware of these fragilizing osteopathies in order to improve both diagnosis and treatment.


Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Calcification, Physiologic/drug effects , Osteomalacia/drug therapy , Osteoporosis/drug therapy , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized/therapeutic use , Bone and Bones/drug effects , Female , Fractures, Bone/drug therapy , France , Humans
4.
Ann Endocrinol (Paris) ; 78 Suppl 1: S11-S20, 2017 Oct.
Article in French | MEDLINE | ID: mdl-29157485

ABSTRACT

The 2017 Endocrine Society annual meeting included several communications and debates on the conservative adrenal surgery in bilateral hereditary pheochromocytomas (BHP), bilateral adrenal macronodular hyperplasia (BAMH) and primary hyperaldosteronism (PHA). The general principle is to preserve a part of the adrenal cortex to prevent the occurrence of a definitive adrenal insufficiency. In BHP, cortical sparing surgery allows more than 50% of patients to maintain normal corticotropic function at 10 years with a low recurrence rate (~ 10%). Since the adrenal medulla cannot be removed entirely, recurrence seems inevitable and long-term follow-up is essential. Individual risk of malignancy must be taken into account. In BAMH responsible for Cushing syndrome, unilateral adrenalectomy induces a normalization of urinary free cortisol in 92 to 100% of cases and even corticotropic insufficiency in 40 to 100% of cases. This is most often transient. Late recurrences of Cushing's syndrome may occur in 13 to 60% of cases. Prolonged patient monitoring is therefore essential. In PAH with lateralized aldosterone production, minimally invasive partial adrenal surgery, which consists of removing only the adrenal adenoma visualized at TDM, allows an improvement blood pressure in about 94% of patients. However, failure or recurrence may occur. Its place therefore remains marginal in the treatment of the lateralized PAHs.


Subject(s)
Adrenal Cortex/surgery , Adrenal Gland Neoplasms/surgery , Adrenal Medulla/surgery , Hyperaldosteronism/surgery , Multiple Endocrine Neoplasia Type 2a/surgery , Organ Sparing Treatments/methods , Pheochromocytoma/surgery , Adrenal Cortex/metabolism , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/metabolism , Adrenal Medulla/metabolism , Endocrine Surgical Procedures/methods , Humans , Hyperaldosteronism/etiology , Multiple Endocrine Neoplasia Type 2a/complications , Multiple Endocrine Neoplasia Type 2a/metabolism , Pheochromocytoma/complications , Pheochromocytoma/metabolism
5.
J Clin Endocrinol Metab ; 101(5): 2099-104, 2016 05.
Article in English | MEDLINE | ID: mdl-27003306

ABSTRACT

CONTEXT: Premature ovarian insufficiency (POI) may be secondary to chemotherapy, radiotherapy, or environmental factors. Genetic causes are identified in 20-25% of cases, but most POI cases remain idiopathic. OBJECTIVE: This study aimed to identify new genes involved in POI and to characterize the implication of CPEB1 gene in POI. DESIGN AND SETTING: This was a case report and cohort study replicate conducted in academic medical centers. PATIENTS AND METHODS: A deletion including CPEB1 gene was first identified in a patient with primary amenorrhea. Secondly, 191 sporadic POI cases and 68 familial POI cases were included. For each patient, karyotype was normal and FMR1 premutation was excluded. Search for CPEB1 deletions was performed by quantitative multiplex PCR of short fluorescent fragments or DNA microarray analysis. Gene sequencing of CPEB1 was performed for 95 patients. RESULTS: We identified three patients carrying a microdeletion in band 15q25.2. The proximal breakpoint, for the three patients, falls within a low-copy repeat region disrupting the CPEB1 gene, which represents a strong candidate gene for POI as it is known to be implicated in oocyte meiosis. No mutation was identified by sequencing CPEB1 gene. Therefore, heterozygous deletion of CPEB1 gene leading to haploinsufficiency could be responsible for POI in humans. CONCLUSION: Microdeletions of CPEB1 were identified in 1.3% of patients with POI, whereas no mutation was identified. This microdeletion is rare but recurrent as it is mediated by nonallelic homologous recombination due to the existence of low-copy repeats in the region. This result demonstrates the importance of DNA microarray analysis in etiological evaluation and counseling of patients with POI.


Subject(s)
Gene Deletion , Menopause, Premature/genetics , Primary Ovarian Insufficiency/genetics , Transcription Factors/genetics , mRNA Cleavage and Polyadenylation Factors/genetics , Adult , Cohort Studies , Female , Humans , Mutation
7.
Eur J Endocrinol ; 173(6): 819-26, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26392472

ABSTRACT

BACKGROUND: MEN1, which is secondary to the mutation of the MEN1 gene, is a rare autosomal-dominant disease that predisposes mutation carriers to endocrine tumors. Most studies demonstrated the absence of direct genotype-phenotype correlations. The existence of a higher risk of death in the Groupe d'étude des Tumeurs Endocrines-cohort associated with a mutation in the JunD interacting domain suggests heterogeneity across families in disease expressivity. This study aims to assess the existence of modifying genetic factors by estimating the intrafamilial correlations and heritability of the six main tumor types in MEN1. METHODS: The study included 797 patients from 265 kindred and studied seven phenotypic criteria: parathyroid and pancreatic neuroendocrine tumors (NETs) and pituitary, adrenal, bronchial, and thymic (thNET) tumors and the presence of metastasis. Intrafamilial correlations and heritability estimates were calculated from family tree data using specific validated statistical analysis software. RESULTS: Intrafamilial correlations were significant and decreased along parental degrees distance for pituitary, adrenal and thNETs. The heritability of these three tumor types was consistently strong and significant with 64% (s.e.m.=0.13; P<0.001) for pituitary tumor, 65% (s.e.m.=0.21; P<0.001) for adrenal tumors, and 97% (s.e.m.=0.41; P=0.006) for thNETs. CONCLUSION: The present study shows the existence of modifying genetic factors for thymus, adrenal, and pituitary MEN1 tumor types. The identification of at-risk subgroups of individuals within cohorts is the first step toward personalization of care. Next generation sequencing on this subset of tumors will help identify the molecular basis of MEN1 variable genetic expressivity.


Subject(s)
Adrenal Gland Neoplasms/genetics , Bronchial Neoplasms/genetics , Multiple Endocrine Neoplasia Type 1/genetics , Neuroendocrine Tumors/genetics , Pancreatic Neoplasms/genetics , Parathyroid Neoplasms/genetics , Pituitary Neoplasms/genetics , Thymus Neoplasms/genetics , Adolescent , Adrenal Gland Neoplasms/epidemiology , Adult , Age Distribution , Bronchial Neoplasms/epidemiology , Child , Child, Preschool , Cohort Studies , Female , Genetic Predisposition to Disease , Humans , Infant , Infant, Newborn , Male , Middle Aged , Neuroendocrine Tumors/epidemiology , Pancreatic Neoplasms/epidemiology , Parathyroid Neoplasms/epidemiology , Pedigree , Pituitary Neoplasms/epidemiology , Thymus Neoplasms/epidemiology , Young Adult
8.
Ann Endocrinol (Paris) ; 76(6 Suppl 1): S39-50, 2015 Oct.
Article in French | MEDLINE | ID: mdl-26776288

ABSTRACT

Pregnancy is an immunological paradox that implies that a semi-allogeneic fetus is not rejected by the maternal immune system, from implantation of the embryo to delivery. Progesterone (P4), estradiol (E2) and human chorionic gonadotropin (hCG), contribute to the transformation of immune cells in a transient tolerance state, necessary to the maintenance of pregnancy. The effects of pregnancy hormones depend probably of their maternal plasma level. hCG is dangerous at high concentrations because it can stimulate autoantibodies production, whereas in physiological concentrations, hCG, P4 and E2 upregulate immune response expanding regulatory T and B cells, allowing the fetus to grow within the maternal uterus in a protective environment. A second example of fetal-maternal relation found recently is the role of maternal nutrition on development of the fetal hypothalamic neurons. Experiments in mice fed on a high fat diet reveal a critical timing when altered maternal metabolism affect formation of hypothalamic neurocircuits of the offspring and predispose him to long-term metabolic disorders.


Subject(s)
Chorionic Gonadotropin/physiology , Estradiol/physiology , Maternal-Fetal Exchange/physiology , Progesterone/physiology , Animals , Autoimmune Diseases , Female , Humans , Hypothalamus/embryology , Immunity , Mice , Pregnancy
9.
Ann Endocrinol (Paris) ; 75 Suppl 1: S21-36, 2014 Oct.
Article in French | MEDLINE | ID: mdl-25617920

ABSTRACT

Today, primary hyperparathyroidism (PHPT) is frequently diagnosed at an asymptomatic stage. New international guidelines presented at the Endocrine Society congress update the management of this disease. Normocalcemic PHPT is part of the diagnostic spectrum of PHPT, its natural history is poorly known, and monitoring is proposed once secondary HPT has been eliminated. Bone involvement, classically predominant in cortical bone, also affects trabecular bone. Osteodensitometry is poorly effective at the vertebral level and new methods (trabecular bone score [TBS], vertebral fracture assessment [VFA]) should improve the assessment of the risk of fracture. The kidney is the most frequently symptomatic organ, and an imaging workup as well as urinary tests are recommended in all patients when searching for causes of lithiasis or nephrocalcinosis. More than 10% of PHPT cases are related to a germinal mutation: these patients should be identified to optimize their management and that of their relatives. Medical treatment is reserved for patients for whom surgery is not indicated or possible: cinacalcet is effective for calcemia, the bisphosphonates are effective for bone involvement. Vitamin D deficiency can be corrected as long as calcemia and creatinuria are monitored. Surgical treatment is recommended in case of pronounced hypercalcemia, bone or renal involvement, and age less than 50 years and in patients in whom monitoring is refused or impossible. Studies have shown that asymptomatic PHPT evolves little in monitored patients.


Subject(s)
Hyperparathyroidism, Primary/diagnosis , Hyperparathyroidism, Primary/therapy , Adult , Aged , Bone Density , Calcium/blood , Cinacalcet , Diphosphonates/therapeutic use , Endocrinology , Fractures, Bone , General Surgery , Humans , Hypercalcemia/drug therapy , Hypercalcemia/etiology , Hyperparathyroidism, Primary/complications , Infant , Infant, Newborn , Lithiasis/etiology , Middle Aged , Naphthalenes/therapeutic use , Nephrocalcinosis/etiology , Practice Guidelines as Topic , Risk Factors , Societies, Medical , Vitamin D Deficiency/complications , Vitamin D Deficiency/drug therapy
10.
Ann Endocrinol (Paris) ; 73 Suppl 1: S45-54, 2012 Oct.
Article in French | MEDLINE | ID: mdl-23089381

ABSTRACT

The silent pheochromocytoma, a hidden form of pheochromocytoma, exposes the patient to an increased risk of mortality if the diagnosis is not established on time. Biological diagnosis of pheochromocytoma can be difficult. Catecholamine secretion is dependent on tumor size and a large number of physiological, pharmacological, lifestyle modifications and sampling conditions influence the measurement of urinary and plasma metanephrines. The prevalence of pheochromocytoma is 2% among adrenal incidentaloma smaller than 3 cm (2/3 of tumors). Recent studies suggest the almost zero risk of pheochromocytoma among these tumors if they are hypodense (<10 housefield units) on adrenal tomography. Addison's disease is a pathology affecting about 1 in 8000. Immunopathology is still unknown, but some elements advocated the hypothesis of a predominant cell-mediated immunity in particular Interferon-gamma production by CD4 T lymphocytes in the presence of an epitope from the 21-hydroxylase, as well as IgG1 subtype produced by activated B lymphocytes, autoantibodies do appear to be a simple marker of the disease. Subclinical Addison's disease is defined by the presence of anti-21-hydroxylase autoantibodies, without clinical symptoms. It evolves faster to the clinical phase in young subjects, male, having high levels of autoantibodies and with an initially impaired adrenal function. Dosage of ACTH, plasma renin active, and basal cortisol and after Synacthen allow to discriminate the subjects with low or high risk of evolution and establish an appropriate monitoring.


Subject(s)
Addison Disease , Adrenal Gland Neoplasms , Pheochromocytoma , Addison Disease/diagnosis , Addison Disease/immunology , Addison Disease/physiopathology , Adrenal Gland Neoplasms/diagnosis , Adrenal Gland Neoplasms/epidemiology , Adrenal Gland Neoplasms/pathology , Adrenal Glands/physiopathology , Adrenocorticotropic Hormone/blood , Autoantibodies/blood , CD4-Positive T-Lymphocytes/immunology , Cosyntropin , Humans , Hydrocortisone/blood , Immunity, Cellular , Interferon-gamma/biosynthesis , Male , Metanephrine/blood , Metanephrine/urine , Pheochromocytoma/diagnosis , Pheochromocytoma/epidemiology , Pheochromocytoma/pathology , Renin/blood , Steroid 21-Hydroxylase/immunology
11.
Eur J Obstet Gynecol Reprod Biol ; 163(1): 47-51, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22512827

ABSTRACT

OBJECTIVE: Several studies have shown an increased frequency of chromosomal aberrations in female partners of couples examined prior to intracytoplasmic sperm injection (ICSI). A retrospective cohort study was performed to determine whether 45,X/46,XX mosaicism affects the outcomes of in vitro fertilization (IVF) or ICSI. STUDY DESIGN: Forty-six women with a 45,X/46,XX karyotype with 6-28% of aneuploidy were compared with 59 control women (46,XX), matched for age, from the female population who underwent IVF or ICSI between 1 January 1996 and 31 December 2006 at the Reproductive Medicine Unit at Brest University Hospital. The outcomes of 254 treatment cycles were compared according to patient karyotype. RESULTS: No difference was found in the number of retrieved oocytes (8.9 ± 5.5 vs 8.5 ± 4.7; p=0.56) or the number of mature oocytes (7.4 ± 4.7 vs 6.9 ± 4.2; p=0.49) between the 45,X/46,XX group and the 46,XX group, respectively. Fertilization rates did not differ between the groups for either IVF or ICSI. In addition, no difference was found in the pregnancy rate by cycle (17.4% vs 18.7%, respectively; p=0.87). The percentage of first-trimester miscarriages was similar in both groups (13.6% vs 12.5%, respectively; p=0.51). CONCLUSION: 45,X/46,XX mosaicism with 6-28% of aneuploidy has no adverse effect on the outcomes of IVF or ICSI among women referred to assisted reproductive technologies.


Subject(s)
Chromosomes, Human, X , Mosaicism , Adult , Aneuploidy , Cohort Studies , Female , Fertilization in Vitro , Humans , Infertility, Female/genetics , Infertility, Female/therapy , Male , Pregnancy , Retrospective Studies , Sperm Injections, Intracytoplasmic
12.
Gynecol Obstet Fertil ; 40(3): e1-4, 2012 Mar.
Article in French | MEDLINE | ID: mdl-22342109

ABSTRACT

Cushing's syndrome is a rare condition in the general population (1/1000000) and is even less common during pregnancy. We report the case of a patient cared at 27 weeks of gestation (wg) for hypertension and electolyte disturbances. Cushing's syndrome was confirmed by salivary cortisol and ACTH assessment. RMN revealed a 9 cm left adrenal tumor. Severe hypertension and electolyte disturbances on the one hand, and diagnostic uncertainty on the other hand, imposed adrenalectomy at 29 wg. Twelve days later, fetal distress led to a caesarian section and birth of a well being male baby.


Subject(s)
Adrenal Gland Neoplasms/diagnosis , Adrenocortical Carcinoma/diagnosis , Cushing Syndrome/diagnosis , Hypertension/diagnosis , Pregnancy Complications, Neoplastic/diagnosis , Adrenal Gland Neoplasms/complications , Adrenal Gland Neoplasms/surgery , Adrenalectomy , Adrenocortical Carcinoma/complications , Adrenocortical Carcinoma/surgery , Adrenocorticotropic Hormone/blood , Adult , Cushing Syndrome/etiology , Cushing Syndrome/surgery , Female , Humans , Hydrocortisone/analysis , Hypertension/etiology , Infant, Newborn , Live Birth , Magnetic Resonance Imaging , Male , Pregnancy , Pregnancy Complications, Neoplastic/surgery , Saliva/chemistry , Severity of Illness Index
13.
Ann Endocrinol (Paris) ; 72 Suppl 1: S1, 2011 Oct.
Article in French | MEDLINE | ID: mdl-22008271
14.
Ann Endocrinol (Paris) ; 72 Suppl 1: S15-22, 2011 Oct.
Article in French | MEDLINE | ID: mdl-22008272

ABSTRACT

Prevalence of osteoporosis, a systemic disease characterized by an impairment of bone mass, will continue to increase due to an ageing population and result in greater risks of fractures with disastrous medical and socioeconomic consequences. A better understanding of the regulation pathway of bone remodeling has led to the identification of new therapeutic targets. Denosumab, a monoclonal antibody against Receptor Activator of Nuclear factor κB-ligand (key molecule in osteoclastogenesis) is a fast-working, reversible antiresorptive treatment. A subcutaneous injection is required twice a year, a significant advantage over bisphosphonates whose efficiency is limited by an inadequate long-term compliance. The only anabolic agent currently available, Teriparatide (parathyroid hormone residues 1-34), administered daily via subcutaneous injection, stimulates both sides of bone remodeling in favour of bone formation. Anti-sclerostin antibodies neutralize an inhibitor of Wnt pathway, the master switch for osteoblastic differentiation, and meet the challenge of pioneering an anabolic drug that does not increase bone resorption. If the tolerance of these promising treatments is good in clinical trials of short duration, their implication in signaling pathways affecting various tissues means that one has to keep a very close watch on their long-term potential risks. Finally, the endocrinologists must be aware that the local regulating factors of bone remodeling recently identified (sclerostin, osteoprotegerin) seem to be the key mediators of hormones with bone tropism.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Bone Morphogenetic Proteins/antagonists & inhibitors , Osteoporosis/drug therapy , Adaptor Proteins, Signal Transducing , Animals , Antibodies, Monoclonal, Humanized , Bone Density Conservation Agents/therapeutic use , Bone Remodeling/drug effects , Clinical Trials as Topic , Denosumab , Diphosphonates/therapeutic use , Female , Genetic Markers , Humans , Male , Mice , NF-kappa B/antagonists & inhibitors , Osteoporosis, Postmenopausal/drug therapy , Osteoprotegerin/metabolism , Patient Compliance , RANK Ligand/antagonists & inhibitors , Rats , Teriparatide/therapeutic use , Treatment Outcome , Wnt Signaling Pathway/drug effects
15.
J Gynecol Obstet Biol Reprod (Paris) ; 39(8 Suppl 2): S289-98, 2010 Dec.
Article in French | MEDLINE | ID: mdl-21185480

ABSTRACT

Women who had gestational diabetes must have their glycemia closely checked after delivery to insure complete normalization. Few studies are published but breast feeding does not seem to modify the metabolic profile of the mother or the children. Contraception must take account associated risk factors. Very few studies are published and none notified a significant modification of the carbohydrate metabolism with hormonal contraception, either estroprogestative or progestative only. But associated obesity, hypertension or dyslipidemia need the prescription of a contraception with no vascular secondary effect. In these cases an intrauterine device represents a very good choice.


Subject(s)
Contraception , Diabetes, Gestational , Postnatal Care , Breast Feeding , Contraceptives, Oral, Hormonal , Diabetes, Gestational/therapy , Female , Humans , Infant, Newborn , Practice Guidelines as Topic , Pregnancy
16.
Diabetes Metab ; 36(6 Pt 2): 566-74, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21163421

ABSTRACT

Women who have had gestational diabetes mellitus must be monitored in the immediate postpartum period to ensure that blood glucose levels return to normal without further treatment. In the few studies performed specifically in these women, those that breastfed did not have a different metabolic profile, at least during the period of breastfeeding; the metabolic profiles of children born to women that had gestational diabetes and that breastfed also did not differ from those that were not breastfed. The choice of contraception must mainly take into consideration the associated risk factors. The studies, even if few have specifically focused on women with a history of gestational diabetes, have not demonstrated a significant disturbance of glucose metabolism while using hormonal contraception, whether combined oral oestrogen/progestogen or progestogen-only contraception. However, the presence of obesity, hypertension, or dyslipidaemia must direct the choice of contraception towards one without cardiovascular consequences. In these cases, the intrauterine device is an excellent choice.


Subject(s)
Contraception , Diabetes, Gestational , Postpartum Period , Adult , Breast Feeding , Child , Female , Humans , Pregnancy
17.
Diabetes Metab ; 36(1): 64-70, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20060765

ABSTRACT

AIM AND METHODS: The present study compared the clinical and metabolic characteristics of latent autoimmune diabetes in adults (LADA) with type 2 diabetes, as well as the residual beta-cell function and progression to insulin treatment, over a 2-year follow-up period, of antibody (Ab)-positive and Ab-negative patients who achieved tight glycaemic control (HbA(1c) 7.0+/-0.8% and 6.5+/-0.9%, respectively, at the time of entry into the study). RESULTS: Glutamic acid decarboxylase antibodies (GADA) and/or islet cell antibodies (ICA) were detected in 10% of patients presenting with non-insulin-dependent diabetes. Around half of Ab-positive patients required insulin treatment during the follow-up. Ab-positive patients displayed lower stimulated C-peptide levels both at entry and during the follow-up compared with Ab-negative patients, although no significant decline in C-peptide levels was observed in either subgroup over two years. Nevertheless, Ab-positive patients progressed more frequently to insulin treatment, and stimulated C-peptide tended to decrease in LADA patients who subsequently required insulin, whereas it remained stable in those who were non-insulin-dependent. In those who progressed, the trend towards C-peptide decline persisted even after starting insulin treatment. CONCLUSION: LADA patients demonstrate lower residual beta-cell function than do type 2 diabetes patients. However, those who achieve tight metabolic control do not present with a rapid decline in beta-cell function. Further studies are needed to determine the optimal treatment strategy in such patients.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 1/metabolism , Diabetes Mellitus, Type 1/pathology , Hypoglycemic Agents/therapeutic use , Insulin-Secreting Cells/pathology , Insulin/therapeutic use , Adult , Age of Onset , Aged , Biomarkers/blood , Body Mass Index , C-Peptide/blood , Cross-Sectional Studies , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/drug therapy , Disease Progression , Female , Humans , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Male , Middle Aged , Prospective Studies
18.
Eur J Endocrinol ; 162(3): 617-23, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19996197

ABSTRACT

OBJECTIVE: Turner's syndrome (TS) is well known, but prognosis for 45,X/46,XX mosaicism below 30% of aneuploidy has not been established. We evaluated differences in clinical features and biological parameters between patients with numerical sex chromosome mosaicism diagnosed incidentally and control women. DESIGN: Retrospective observational study of clinical features and biological parameters. METHODS: Standard endocrinological and gynecological examination was done and early-follicular-phase blood values were collected from the medical records of women aged 21-43, who were referred to our ward from 1996 to 2006 because of infertility and were karyotyped. Seventy-one women with sex chromosome mosaicism (45,X/46,XX) ranging from 4 to 28% were assigned a chromosomally normal woman (46,XX) matched according to age (n=71). RESULTS: In group 45,X/46,XX, 8% or more of aneuploidy accounted for a smaller height compared to controls (P=0.01). Body mass index was increased from 6% of aneuploidy (P=0.02) and was positively correlated to the percentage of 45,X cells (P=0.0001); menarche occurred earlier from 10% of aneuploidy (P=0.01) and was inversely correlated to the percentage of 45,X cells (P=0.045). No difference was found between the groups for FSH, LH, estradiol, inhibin B, and TSH values. Spontaneous abortions were more frequent in case of mosaicism (P=0.01), and recurrence was positively correlated to the percentage of aneuploidy (P=0.008). CONCLUSION: Sex chromosome mosaicism is responsible for clinical changes from 6% of aneuploidy, corresponding to the main phenotypical features of TS.


Subject(s)
Aneuploidy , Chromosomes, Human, X/genetics , Infertility, Female/genetics , Mosaicism , Turner Syndrome/genetics , Abortion, Spontaneous/genetics , Adult , Analysis of Variance , Body Height/genetics , Body Mass Index , Chi-Square Distribution , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Humans , Infertility, Female/blood , Inhibins/blood , Karyotyping , Luteinizing Hormone/blood , Menarche/genetics , Retrospective Studies , Thyrotropin/blood , Turner Syndrome/blood
20.
J Endocrinol Invest ; 29(4): 353-7, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16699303

ABSTRACT

We report the case of a 29-yr-old woman who first presented an aseptic meningitis at the beginning of a pregnancy. She was admitted one month later with headaches and vomiting. Panhypopituitarism with diabetes insipidus was diagnosed. Magnetic resonance imaging (MRI) data suggested the existence of lymphocytic infundibulohypophysitis, with inflammation of the suprasellar area. No new symptoms were noticed until 6 months later when this patient pointed out troubles of the visual field, due to a compression of the optic chiasma. Three boluses of 1 g methylprednisolone were prescribed, with no effects. After delivery, the defects of the visual field increased. A neurosurgical intervention was decided. Diagnosis of Rathke's cleft cyst (RCC) was made. We concluded that this patient presented a rupture of a RCC, which occurred at the beginning of pregnancy, associated later with panhypopituitarism with diabetes insipidus, due to a probable hypophysitis. The end of the pregnancy was marked by consequences of an increased volume of the RCC. To our knowledge, this case is the first described during pregnancy.


Subject(s)
Central Nervous System Cysts/complications , Pituitary Diseases/diagnosis , Pregnancy Complications/diagnosis , Adult , Central Nervous System Cysts/surgery , Diabetes Insipidus/etiology , Diagnosis, Differential , Female , Humans , Hypopituitarism/etiology , Infant, Newborn , Inflammation/diagnosis , Magnetic Resonance Imaging , Meningitis, Aseptic/diagnosis , Pregnancy , Rupture, Spontaneous , Visual Fields
SELECTION OF CITATIONS
SEARCH DETAIL